Azenta (NASDAQ:AZTA – Get Free Report) will likely be announcing its Q3 2026 results before the market opens on Tuesday, August 4th. Analysts expect Azenta to post earnings of $0.1138 per share and revenue of $149.2380 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earning report for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:30 AM ET.
Azenta (NASDAQ:AZTA – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of $0.12 by ($0.16). Azenta had a positive return on equity of 1.23% and a negative net margin of 30.49%.The business had revenue of $144.79 million during the quarter, compared to analyst estimates of $148.47 million. During the same quarter last year, the firm earned $0.01 EPS. The business’s revenue was up 1.4% on a year-over-year basis.
Azenta Trading Down 2.3%
Azenta stock opened at $28.13 on Friday. The firm has a market capitalization of $1.30 billion, a P/E ratio of -7.10 and a beta of 1.37. Azenta has a twelve month low of $15.93 and a twelve month high of $41.73. The stock’s fifty day simple moving average is $24.68 and its 200-day simple moving average is $25.81.
Institutional Investors Weigh In On Azenta
Analyst Ratings Changes
Several research analysts recently commented on AZTA shares. Weiss Ratings raised Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. Needham & Company LLC reduced their price target on Azenta from $44.00 to $33.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $40.40.
View Our Latest Analysis on AZTA
Azenta Company Profile
Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.
In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.
Read More
- Five stocks we like better than Azenta
- Popular’s Earnings Beat Shows Why This Bank Stock Keeps Climbing
- ABB’s Rotork Deal Could Put These Flow Control Stocks Back in Focus
- GE HealthCare Stock Climbs on Vital Diagnostics Demand
- Lost in Space: Why Aerospace Valuations Are Plummeting Right Now
Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.
